Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236340533> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W4236340533 endingPage "524" @default.
- W4236340533 startingPage "524" @default.
- W4236340533 abstract "Abstract Children with acute lymphoblastic leukemia (ALL) are at increased risk for venous thromboembolism (VTE), however, not all children experience a VTE. Developing a predictive model for determining children at increased risk would be beneficial in targeting interventional studies to only high risk groups. A recent meta-analysis of studies in VTE in children with ALL identified four potential risk factors: treatment with Escherichia coli asparaginase (CASP), concomitant use of steroids, presence of central venous lines and thrombophilic genetic abnormalities. As VTE in childhood ALL is well recognized as serious clinical problem and due to the lack of studies on prevention, the standard of practice varies and some centres use enoxaparin prophylaxis for these children. However, the risks and benefits of the intervention are unknown. The aim of the study was to develop a simple model for predicting ALL-chemotherapy-associated VTE using baseline clinical and laboratory variables, and to evaluate, on an explorative basis, the increasing off-label use of enoxaparin for VTE prophylaxis in ALL children. For development of the risk model the predictive variables were scored as follows: treatment with CASP (5000–10000/m2) in combination with prednisone or dexamethasone, presence of central venous lines, thrombophilic genetic abnormalities, e.g. positive family history for VTE or identification of a single thrombophilic trait (1 point each), or carrier status of combined thrombophilic traits (2 points). A definition of VTE risk by score was low (1–2) and high (□ 3). The risk score was than prospectively validated in an independent cohort of 136 newly recruited patients enrolled into the German database. Seven patients were excluded (lost to follow-up n=2; death n=2, secondary malignancy, VTE before ALL-onset, infant < 12 months of age: each n=1). The cumulative VTE rates at 3.5 months in the validation cohorts were 3.6% (95% CI 1%–9%) in the low-risk group (4 of 112), and 47% (95%CI 23%–72%) in the high-risk category (8 of 17). In multivariate analysis [Cox regression] the high risk group was significantly associated with VTE when compared to the low risk group even after adjusting for age at ALL-onset, duration of CASP administration, steroid administered (prednisone/dexamethasone), and presence or absence of enoxaparin prophylaxis [hazard/95%CI: 4.16/1.13–15.34]. The negative predictive value for VTE was 96.3% [95%CI: 92.9–99.8]. Early enoxaparin prophylaxis reduced the absolute VTE-risk about 60% [95%CI: 23–96]. Therefore, the model can identify ALL-children with an increased risk for symptomatic VTE." @default.
- W4236340533 created "2022-05-12" @default.
- W4236340533 creator A5020308121 @default.
- W4236340533 creator A5042661460 @default.
- W4236340533 creator A5044350124 @default.
- W4236340533 creator A5051881642 @default.
- W4236340533 creator A5060098976 @default.
- W4236340533 creator A5069210529 @default.
- W4236340533 date "2008-11-16" @default.
- W4236340533 modified "2023-09-29" @default.
- W4236340533 title "Validation of a Predictive Model for Indentifying An Increased Risk for Thromboembolism in Children with Acute Lymphoblastic Leukemia: Results of a Multicenter Cohort Study" @default.
- W4236340533 doi "https://doi.org/10.1182/blood.v112.11.524.524" @default.
- W4236340533 hasPublicationYear "2008" @default.
- W4236340533 type Work @default.
- W4236340533 citedByCount "0" @default.
- W4236340533 crossrefType "journal-article" @default.
- W4236340533 hasAuthorship W4236340533A5020308121 @default.
- W4236340533 hasAuthorship W4236340533A5042661460 @default.
- W4236340533 hasAuthorship W4236340533A5044350124 @default.
- W4236340533 hasAuthorship W4236340533A5051881642 @default.
- W4236340533 hasAuthorship W4236340533A5060098976 @default.
- W4236340533 hasAuthorship W4236340533A5069210529 @default.
- W4236340533 hasConcept C126322002 @default.
- W4236340533 hasConcept C177713679 @default.
- W4236340533 hasConcept C187212893 @default.
- W4236340533 hasConcept C2778461978 @default.
- W4236340533 hasConcept C2778720950 @default.
- W4236340533 hasConcept C2778904437 @default.
- W4236340533 hasConcept C2909962599 @default.
- W4236340533 hasConcept C71924100 @default.
- W4236340533 hasConcept C72563966 @default.
- W4236340533 hasConceptScore W4236340533C126322002 @default.
- W4236340533 hasConceptScore W4236340533C177713679 @default.
- W4236340533 hasConceptScore W4236340533C187212893 @default.
- W4236340533 hasConceptScore W4236340533C2778461978 @default.
- W4236340533 hasConceptScore W4236340533C2778720950 @default.
- W4236340533 hasConceptScore W4236340533C2778904437 @default.
- W4236340533 hasConceptScore W4236340533C2909962599 @default.
- W4236340533 hasConceptScore W4236340533C71924100 @default.
- W4236340533 hasConceptScore W4236340533C72563966 @default.
- W4236340533 hasIssue "11" @default.
- W4236340533 hasLocation W42363405331 @default.
- W4236340533 hasOpenAccess W4236340533 @default.
- W4236340533 hasPrimaryLocation W42363405331 @default.
- W4236340533 hasRelatedWork W11357016 @default.
- W4236340533 hasRelatedWork W14644975 @default.
- W4236340533 hasRelatedWork W17959953 @default.
- W4236340533 hasRelatedWork W21528425 @default.
- W4236340533 hasRelatedWork W22483912 @default.
- W4236340533 hasRelatedWork W4722137 @default.
- W4236340533 hasRelatedWork W683957 @default.
- W4236340533 hasRelatedWork W777628 @default.
- W4236340533 hasRelatedWork W8808446 @default.
- W4236340533 hasRelatedWork W9761544 @default.
- W4236340533 hasVolume "112" @default.
- W4236340533 isParatext "false" @default.
- W4236340533 isRetracted "false" @default.
- W4236340533 workType "article" @default.